New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial

NCT ID NCT06714617

Ongoing Disease control Sponsor: SystImmune Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard treatment before.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma breast cancer breast carcinoma breast neoplasm endometrium neoplasm fallopian tube cancer fallopian tube neoplasm gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma HER2 positive breast carcinoma non-small cell lung carcinoma ovarian cancer ovarian carcinoma peritoneum cancer primary peritoneal carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE III ENDOMETRIAL NEOPLASMS FALLOPIAN TUBE CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER HER2 GENE MUTATION HER2 POSITIVE HER2-POSITIVE METASTATIC BREAST CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER PERITONEAL CANCER SOLID TUMOR, ADULT UNRESECTABLE BREAST CARCINOMA UROTHELIAL CARCINOMA BLADDER

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hematology Oncology Associates of the Treasure Cost

Port Saint Lucie, Florida, 34952, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
SCRI-Denver HealthOne

Denver, Colorado, 37203, United States
SCRI-Florida Cancer Center Specialists Lake Mary

Lake Mary, Florida, 32746, United States
SCRI-Florida Cancer Center Specialists Sarasota

Sarasota, Florida, 34236, United States
SCRI-Oncology Partners

Nashville, Tennessee, 37203, United States
SCRI-Sidney Kimmel Cancer Center

Philadelphia, Pennsylvania, 19107, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.